Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
Impact of expanding access to GLP-1 receptor agonists, dual gastric inhibitory polypeptide and GLP-1 receptor agonists quantified
In-Utero Sugar Restriction Cuts Offspring’s Risk for Diabetes, Hypertension
35 percent lower risk for diabetes, 20 percent reduced risk for hypertension seen for sugar restriction in first three years after conception
Prevalence of Diabetes 15.8 Percent in U.S. Adults From 2021 to 2023
Prevalence of diagnosed diabetes was 11.3 percent and undiagnosed diabetes was 4.5 percent; prevalence higher for men
Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
Policies About Late-Career Physicians Are Considered Successful
Policies varied in the testing required, funding, processes after a positive screening result, and decision-making around concerning results
Improvement Seen in Some Features of PCOS With Weight Loss Interventions
Interventions associated with significantly greater improvements in HOMA-IR, free androgen index, menstrual frequency
Semaglutide Linked to Reduced Risk for Alzheimer Diagnosis in T2DM
Semaglutide linked to significantly reduced risk, most strongly compared with insulin and most weakly with other GLP-1 RAs
ACG: GLP-1 RAs Tied to Lower Risk for Early-Onset Colorectal Cancer
Findings seen in people with type 2 diabetes
ASN: 1990 to 2021 Saw Global Rise in Chronic Kidney Disease Cases, Deaths in...
Type 2 diabetes and hypertension were the major contributors to chronic kidney disease-related deaths among women in 2021
Vasomotor Symptoms During Menopause May Up Risk for Type 2 Diabetes
Women with persistently high VMS have increased risk for diabetes versus those with persistently low VMS
